Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

Seretny, Marta; Currie, Gillian L.; Sena, Emily S.; Ramnarine, Sabrina; Grant, Robin; Macleod, Malcolm; Colvin, Lesley; Fallon, Marie

doi:10.1016/j.pain.2014.09.020

Cited by 1,153 publications

(926 citation statements)

References 65 publications

Supporting

Mentioning

862

Contrasting

Unclassified

Order By: Relevance

“…4 Exposure to certain toxins and chemotherapeutic medications can also lead to the development of chronic pain. 5 Erythromelalgia is a neuropathic pain condition associated with a specific mutation in the SCN9A gene that encodes DNA for alpha subunits of the NaV1.7 voltage gated sodium channels; 6 however, for other chronic pain entities, such as fibromyalgia, no etiology (genetic or otherwise) has yet been identified. 7 All patients who undergo surgery or sustain a traumatic injury suffer from acute pain for a relatively short period of time following tissue injury.…”

Section: Overviewmentioning

confidence: 99%

Genetics of chronic post-surgical pain: a crucial step toward personal pain medicine

Clarke

Katz

Flor

et al. 2014

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Purpose Most patients who undergo surgery or experience a traumatic injury suffer from acute pain that subsides once tissues heal. Nevertheless, the pain remains in 15-30% of patients, sometimes for life, and this chronic post-surgical pain (CPSP) can result in suffering, depression, anxiety, sleep disturbance, physical incapacitation, and an economic burden. The incorporation of genetic knowledge is expected to lead to the development of more effective means to prevent and manage CPSP using tools of personalized pain medicine. The purpose of this review article is to provide an update on the current state of CPSP genetics and its future potential.Principle findings The large variability in CPSP amongst patients undergoing similar surgery suggests that individual factors are significant contributors to CPSP, raising the possibility that CPSP is influenced by genetic determinants. Heritability estimates suggest that about half of the variance in CPSP levels is attributable to genetic variation. These estimates suggest that identifying the genetic underpinnings of CPSP may lead to significant improvements in treatment. Analyzing patients' DNA sequences, blood and salivary pain biomarkers, as well as their analgesic responses to medications will facilitate developing insights into CPSP pathophysiology and inform predictive algorithms to determine a patient's likelihood of developing CPSP even prior to surgery. These algorithms could facilitate effective treatment regimens that will protect against the transition to chronicity in traumatically injured patients or those scheduled for surgery and lead to better therapy for patients who have already developed CPSP.Author contributions Hance Clarke, Joel Katz, Herta Flor, Marcella Rietschel, and Scott Diehl are co-authors of the manuscript and are responsible for revising some of the manuscript. Ze'ev Seltzer is the lead author responsible for revising the manuscript.

show abstract

Section: Overviewmentioning

confidence: 99%

Genetics of chronic post-surgical pain: a crucial step toward personal pain medicine

Clarke

Katz

Flor

et al. 2014

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

show abstract

“…Distorted thermal sensation, pain and nerve damage are the most common and unpleasant side effects of chemotherapy, affecting treatment dosing, patient well‐being, and quality of life and incurring additional costs on health care systems worldwide (Seretny et al., 2014). …”

Section: Introductionmentioning

confidence: 99%

Chemotherapy‐induced neuropathies—a growing problem for patients and health care providers

2016

View full text Add to dashboard Cite

IntroductionChemotherapy‐induced neuropathies are one of the most common side effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunction. Chemotherapy effects on the nervous system vary between different classes of drugs and depend on specific chemical and physical properties of the drug used. The three most neurotoxic classes of anti‐cancer drugs are: platinum‐based drugs, taxanes, and thalidomide and its analogs; other, less neurotoxic but also commonly used drugs are: bortezomib, ixabepilone, and vinca alkaloids.MethodsHere, in this paper, based on our experience and current knowledge, we provide a short review of the most common, neuropathy‐inducing anti‐cancer drugs, describe the most prevalent neuropathy symptoms produced by each of them, and outline preventive measures and treatment guidelines for cancer patients suffering from neuropathy and for their health care providers.ResultsPatients should be encouraged to report any signs of neuropathic pain, alteration in sensory perception, tingling, numbness, burning, increased hot/cold sensitivity and motor dysfunctions as early as possible. If known neurotoxic chemotherapeutics are used, a neurological examination with electrophysiological evaluation should be implemented early in the course of treatment so, both patients and physicians would be better prepared to cope with possible neurotoxic effects.ConclusionsThe use of neurotoxic chemotherapeutics should be closely monitored and if clinically permitted, that is, if a patient shows signs of cancer regression, drug doses should be reduced or combined with other less neurotoxic anti‐cancer medication. If not counteractive, the use of over the counter antineuropathic supplements such as calcium or magnesium might be encouraged. If physically possible, patients should also be encouraged to exercise regularly and avoid factors that might increase nerve damage such as excessive drinking, smoking, or sitting in a cramped position.

show abstract

“…16 In addition, patients who experienced peripheral neuropathy, a side-effect from chemotherapy could be disabled after using antineoplastic agents. 17 One study noticed, in children the lower age could resulted in greater sensitivity of some nerves to vincristine and thus showing a motor predominant neuropathy in children. 18 Patients experiencing this side effects would require reduction or cessation of the chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients

Imam¹,

Ibrahim²,

Palaian³

et al. 2016

JYP

View full text Add to dashboard Cite

Background: Increasing clinical evidence suggests treatment of cancer with neurotoxic agents results in some degree of peripheral neuropathy. Objective: The main objective of the study was to evaluate vincristine induced peripheral neuropathy among Sudanese cancer patients. Methods: A descriptive cross-sectional study was carried out at Radiation and Isotopes Center, Khartoum State, Sudan. All patients suffering from cancer with an age of 18 to 65 years were reviewed. A self-developed data collection form was used to collect the demographic data; drug use history; medical diseases; and vincristine cycles. The World Health Organization criteria were used to grade the side-effects. Data was collected for a period of two months and were analyzed descriptively. Results: Out of 78 patients reviewed, majority were females (n=47, 60.3%). Most of the patients were in the age group of 18-30 (n=27, 34.6%) and 51-60 (n=27, 34.6%) years. Twenty six (33.3%) of the patients took analgesic and 15.3% (n=12) experienced hypertension. Most of the patients went through more than 6 cycles of therapy with vincristine (n=24, 30.9%). Our study showed that 'altered bowel function (i.e constipation)' was the most important neuropathic change, which occurred in 62 (79.5%) of the patients who received vincristine. The second common neuropathic change was the 'lack of ability to go upstairs un-aided', which occurred in 37 (47.4%) of patients receiving vincristine. Majority of the patients (n=37, 47.5%) showed mild paresthesia as graded by the 'WHO grading scale'. Conclusion: More than three-fourth of the cancer patients experienced vincristine induced peripheral neuropathy. Healthcare professionals need some understanding regarding medical management that may decrease occurrence of neuropathy and a better planning and implementing special care for patients at risk.

show abstract

Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

Cited by 1,153 publications

References 65 publications

Genetics of chronic post-surgical pain: a crucial step toward personal pain medicine

Genetics of chronic post-surgical pain: a crucial step toward personal pain medicine

Chemotherapy‐induced neuropathies—a growing problem for patients and health care providers

Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients

Contact Info

Product

Resources

About